Dr. Reddy's rituximab biosimilar wins FDA approval for US market
RDY•FDA approves Dr. Reddy's rituximab biosimilar
- Dr. Reddy’s won U.S. FDA clearance for a rituximab biosimilar, a copy of Roche’s Rituxan, expanding its U.S. biosimilars portfolio.
- Fresenius Kabi secured exclusive U.S. commercialization rights under a prior agreement.
